导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -14.97% | 4099/4773 |
| 近一周 | -2.76% | 4233/5465 |
| 近一月 | -0.36% | 791/5421 |
| 近一季 | -1.40% | 1205/5231 |
| 近半年 | -6.07% | 3147/4920 |
| 近一年 | -10.75% | 3462/4394 |
| 近两年 | 31.65% | 2217/2954 |
| 近三年 | 17.05% | 1581/2253 |
| 成立以来 | 12.27% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-15.57% 4717/4961 |
1.20% 3065/5312 |
- - |
- - |
| 2025 | 12.75% 2679/4813 |
-5.66% 3309/3635 |
6.85% 416/4076 |
6.05% 3554/4524 |
5.47% 439/4813 |
| 2024 | 35.53% 55/3463 |
-2.66% 1402/2808 |
-3.18% 1311/3014 |
42.27% 54/3129 |
1.08% 1123/3463 |
| 2023 | -2.91% 613/2656 |
0.95% 1665/2280 |
-0.04% 356/2385 |
5.51% 86/2515 |
-8.81% 2311/2655 |
| 2022 | -17.10% 550/2207 |
-14.78% 999/1919 |
2.83% 1252/2016 |
-13.89% 988/2113 |
9.86% 193/2208 |
| 2021 | -14.21% 1144/1822 |
-11.11% 1127/1255 |
-2.00% 1188/1330 |
-3.90% 665/1466 |
2.48% 580/1822 |
| 2020 | 11.82% 820/1250 |
-14.30% 957/1028 |
8.68% 817/1067 |
14.48% 274/1164 |
4.86% 827/1184 |
| 2019 | 45.11% 157/1092 |
38.01% 69/754 |
3.55% 47/804 |
-2.92% 717/850 |
4.60% 794/918 |
| 2018 | -21.90% 225/834 |
- - |
- - |
- - |
-10.32% 187/691 |
| 2017 | 21.06% 170/714 |
- - |
- - |
- - |
- - |
| 2016 | -9.48% 263/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 易方达沪深300非银联接A VS. 长安沪深300非周期A(740101) |